Study: | Current study | Hryszko, 2012 [14] | Takeda, 2011 [15] | Prats, 2013 [20] | Wolf, 2013 [13] | Schouten, 2009 [12] | ||
---|---|---|---|---|---|---|---|---|
Patient group | HD | HD | HD | CKD | Iron deficient women, no CKD | Medical outpatients, no CKD | ||
Number of participants | 20 | 22 | 12 | 27 | 47 | 25 | 30 | 8 |
Baseline ferritin (μg/L) | 187 ± 130 | 211 ± 133 | 64.4 ± 32.7 | 31 ± 23 | 67.8 ± 61.7 | 4.4 ± 0.6 | 6.9 ± 1.7 | |
Iron formulation | IS | FCM | Iron dextran | Saccharated ferric oxide | FCM | FCM | Iron dextran | Iron polymaltose |
Iron dose regimen: | 1 dose of 200 mg | 1 dose of 200 mg | 1 dose individualised, mean = 450 mg | 9 doses of 40 mg after dialysis (total = 360 mg) | 1 dose (15 mg/kg to a maximum of 1000 mg, mean = 972 mg) | 1 dose (15 mg/kg to a maximum of 1000 mg, mean = 918 mg) | 1 dose (15 mg/kg to a maximum1,000 mg, mean = 911 mg) | 1 dose (mean = 918 mg, range 500–1600 mg) |
FGF23 measures post-infusion: | 2, 7, 21, 42 days | 2, 7, 21, 42 days | Weeks 1 & 3 | Weeks 1, 3 & 5 | Week 3 & 12 | Days 1, 7, 14, 28 & 35 | Days 1, 7, 14, 28 & 35 | Weekly for up to 7 weeks |
iFGF23 | − | ↓ | ↑ | ↑ | ↑a | − | ↑↑ | |
cFGF23 | − | ↑ | ↓ | ↓↓ | ↓↓ | |||
Ferritin | ↑↑ | ↑↑ | ↑ | ↑ | ↑ | ↑↑a | ↑ | |
Hepcidin | ↑ | ↑↑a | ↑ | ↑↑a | ||||
Phosphate | − | ↓ | − | − | ↓ | ↓ | − | ↓ |